GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (FRA:M8W) » Definitions » Net Interest Income (for Banks)

MediWound (FRA:M8W) Net Interest Income (for Banks)


View and export this data going back to 2014. Start your Free Trial

What is MediWound Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


MediWound Business Description

Industry
Traded in Other Exchanges
Address
42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.